Live Breaking News & Updates on Technology Licensees

Stay updated with breaking news from Technology licensees. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 26th Annual Meeting

/PRNewswire/ REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting, taking. ....

United States , San Francisco , Justind Glenn , Chris Brinzey , Randolph Qian , Zhuo Wang , Dounia Abbadi , Robert Duba , Paul Harmatz , Wei Hua Lee , Aprilr Giles , Samanthaa Yost , Dana Cormack , Nick Pearson , Steven Foltz , Laura Pisani Betancourt , Jessica Gumerson , Elad Firnberg , Los Angeles , Technology Platform , Clinical Development , Research Early Development , American Society Of Gene Cell Therapy , High Resolution Biodistribution Analysis Following Suprachoroidal Administration , Product Development Manufacturing , Technology Platform Licensees ,

REGENXBIO Reports Third Quarter 2021 Financial Results and Operational Highlights

/PRNewswire/ Announced eye care collaboration with AbbVie to develop and commercialize RGX-314 AbbVie and REGENXBIO form a strategic partnership combining. ....

United States , David Rosen , Brendan Burns , Tricia Truehart , Technology Platform , Technology Platform Licensees , Development Expenses , Pivotal Program , Technology Licensees , Technology Products , Drug Administration , American Academy Of Ophthalmology , Exchange Commission , Technology Licensee Program , Healthcare Royalty Management , Pathway Development Consortium , Corporate Communications , Solid Biosciences Inc , Medicines Partnership Bespoke Gene Therapy Consortium , Securities Exchange , Chief Executive Officer , Care Collaboration , Mediated Antibody , American Academy , New Orleans , Hereditary Angioedema ,

REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights

REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , David Rosen , Brendan Burns , Tricia Truehart , Technology Platform , Technology Platform Licensees , Development Expenses , Pivotal Program , Technology Licensees , Retina Society , Technology Products , Ultragenyx Pharmaceutical Inc , Drug Administration , Exchange Commission , Technology Licensee Program , Healthcare Royalty Management , Corporate Communications , Securities Exchange , Annual Scientific Meeting , Chief Executive Officer , Mediated Antibody , Wet Age Related Macular Degeneration , Diabetic Retinopathy , Hereditary Angioedema , Neurodegenerative Diseases , Rare Genetic ,

REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights

REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , David Rosen , Brendan Burns , Tricia Truehart , Technology Platform , Technology Platform Licensees , Development Expenses , Pivotal Program , Technology Licensees , Retina Society , Technology Products , Ultragenyx Pharmaceutical Inc , Drug Administration , Exchange Commission , Technology Licensee Program , Healthcare Royalty Management , Corporate Communications , Securities Exchange , Annual Scientific Meeting , Chief Executive Officer , Mediated Antibody , Wet Age Related Macular Degeneration , Diabetic Retinopathy , Hereditary Angioedema , Neurodegenerative Diseases , Rare Genetic ,

REGENXBIO Reports First Quarter 2021 Financial Results and Operational Highlights

REGENXBIO Reports First Quarter 2021 Financial Results and Operational Highlights
News provided by
Share this article
ROCKVILLE, Md., May 5, 2021 /PRNewswire/
Enrollment ongoing in ATMOSPHERE™, the first of two planned pivotal trials for the subretinal delivery of RGX-314 for the treatment of wet AMD
Continued progress and expansion of Phase II AAVIATE
® trial of RGX-314 utilizing in-office suprachoroidal delivery for the treatment of wet AMD
Began dosing in Phase I/II trial of RGX-121, a one-time gene therapy for MPS II, in pediatric patients over 5 years old
Completed dosing in Cohort 1 of ongoing trial of RGX-111, a one-time gene therapy for MPS I ....

United States , David Rosen , Brendan Burns , Tricia Truehart , Technology Platform , Technology Platform Licensees , Development Expenses , Pivotal Program , Technology Licensees , Technology Products , Ultragenyx Pharmaceutical Inc , Drug Administration , Exchange Commission , Technology Licensee Program , Healthcare Royalty Management , Corporate Communications , Securities Exchange , Audentes Therapeutics Inc , Duchenne Muscular Dystrophy , Chief Executive Officer , Mediated Antibody , Wet Age Related Macular Degeneration , Best Corrected Visual Acuity , Diabetic Retinopathy , Hereditary Angioedema , Neurodegenerative Diseases ,